Wutah dodolan YoY sajrone 12 wulan kepungkur: Terns Pharmaceuticals (TERN)

Terns Pharmaceuticals (TERN) minimizes risks through a broad portfolio of small molecules for metabolism and gastrointestinal therapies. The year-over-year revenue dynamics over 12 months clearly demonstrate a trend where the indicator reached the level of 0.00. Stable demand for the treatment of chronic liver pathologies guarantees sales resilience, while the humanitarian status of the industry eliminates the negative impact of geopolitical factors.
Terns Pharmaceuticals, Inc. (TERN) - rincian metrik lan laporan keuangan

The specific nature of Terns Pharmaceuticals (TERN) development of drugs for the therapy of chronic gastrointestinal and liver pathologies creates high inertia for future revenues due to the regularity of medication intake. By analyzing the relative change in rolling year revenue compared to the same period last year, an investor assesses the percentage growth of total sales over the last twelve months, which allows for the elimination of seasonality and confirms the stability of the fundamental business growth trend.